Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes

Reuters

2025/05/29

Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes

Teva Pharmaceutical Industries Ltd. recently entered into a significant financial agreement involving its subsidiaries, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. On May 28, 2025, these subsidiaries collectively issued a substantial total of €1 billion and $1.2 billion in senior notes, with varying interest rates and maturity dates, to support the company's financial strategy. The Euro Notes, 2030 USD Notes, and 2032 USD Notes were issued under separate indentures with The Bank of New York Mellon serving as trustee. The proceeds from these notes are intended to fund a tender offer with a maximum purchase price of $2.25 billion, cover associated fees and expenses, and potentially repay outstanding debt. This financial move underscores Teva's strategic efforts to manage its financial obligations and optimize its capital structure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129488), on May 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2539409334"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539409334\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2539409334?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539409334","market":"nz","top_or_hot":-1,"title":"Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TEVJF\">Teva Pharmaceutical Industries Ltd.</a> recently entered into a significant financial agreement involving its subsidiaries, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. On May 28, 2025, these subsidiaries collectively issued a substantial total of €1 billion and $1.2 billion in senior notes, with varying interest rates and maturity dates, to support the company's financial strategy. The Euro Notes, 2030 USD Notes, and 2032 USD Notes were issued under separate indentures with The Bank of New York Mellon serving as trustee. The proceeds from these notes are intended to fund a tender offer with a maximum purchase price of $2.25 billion, cover associated fees and expenses, and potentially repay outstanding debt. This financial move underscores Teva's strategic efforts to manage its financial obligations and optimize its capital structure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129488), on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-29 04:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TEVJF\">Teva Pharmaceutical Industries Ltd.</a> recently entered into a significant financial agreement involving its subsidiaries, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. On May 28, 2025, these subsidiaries collectively issued a substantial total of €1 billion and $1.2 billion in senior notes, with varying interest rates and maturity dates, to support the company's financial strategy. The Euro Notes, 2030 USD Notes, and 2032 USD Notes were issued under separate indentures with The Bank of New York Mellon serving as trustee. The proceeds from these notes are intended to fund a tender offer with a maximum purchase price of $2.25 billion, cover associated fees and expenses, and potentially repay outstanding debt. This financial move underscores Teva's strategic efforts to manage its financial obligations and optimize its capital structure.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129488), on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK","symbol_name":"紐約梅隆銀行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL4cC4BQ:1","article_id":"2539409334","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539409334","pubTimestamp":1748463136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Teva Pharmaceutical Industries Ltd. recently entered into a significant financial agreement involving its subsidiaries, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. On May 28, 2025, these subsidiaries collectively issued a substantial total of 1 billion and $1.2 billion in senior notes, with varying interest rates and maturity dates, to support the company's financial strategy. The Euro Notes, 2030 USD Notes, and 2032 USD Notes were issued under separate indentures with The Bank of New York Mellon serving as trustee. The proceeds from these notes are intended to fund a tender offer with a maximum purchase price of $2.25 billion, cover associated fees and expenses, and potentially repay outstanding debt. This financial move underscores Teva's strategic efforts to manage its financial obligations and optimize its capital structure.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK":"纽约梅隆银行","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4135":"资产管理与托管银行","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4588":"碎股","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"梯瓦制药与子公司达成新融资协议，发行10亿欧元和12亿美元优先票据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BK":0.9},"content_text":"Teva Pharmaceutical Secures New Financing Agreement with Subsidiaries, Issuing €1 Billion and $1.2 Billion in Senior Notes\n    \n\nTeva Pharmaceutical Industries Ltd. recently entered into a significant financial agreement involving its subsidiaries, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., and Teva Pharmaceutical Finance Netherlands IV B.V. On May 28, 2025, these subsidiaries collectively issued a substantial total of €1 billion and $1.2 billion in senior notes, with varying interest rates and maturity dates, to support the company's financial strategy. The Euro Notes, 2030 USD Notes, and 2032 USD Notes were issued under separate indentures with The Bank of New York Mellon serving as trustee. The proceeds from these notes are intended to fund a tender offer with a maximum purchase price of $2.25 billion, cover associated fees and expenses, and potentially repay outstanding debt. This financial move underscores Teva's strategic efforts to manage its financial obligations and optimize its capital structure.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-129488), on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}